T. Esaki

发表

1513MO A phase II study of nivolumab plus low dose ipilimumab as first -line therapy in patients with advanced gastric or esophago-gastric junction MSI-H tumor: First results of the NO LIMIT study (WJOG13320G/CA209-7W7)

Y. Komatsu, M. Tsuda, N. Sugimoto, 2023, Annals of Oncology.